

# Elena Moreno

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3497341/elena-moreno-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22  
papers

3,437  
citations

14  
h-index

29  
g-index

29  
ext. papers

5,021  
ext. citations

13.1  
avg, IF

4.29  
L-index

#	Paper	IF	Citations
22	Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 848630	8.4	1
21	Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 873408	8.4	1
20	COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 633680	6.80	30
19	Population Disequilibrium as Promoter of Adaptive Explorations in Hepatitis C Virus. <i>Viruses</i> , <b>2021</b> , 13,	6.2	3
18	Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. <i>Cell Reports</i> , <b>2021</b> , 35, 109133	10.6	27
17	Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. <i>Science</i> , <b>2021</b> , 371, 926-931	33.3	117
16	The Global Phosphorylation Landscape of SARS-CoV-2 Infection. <i>Cell</i> , <b>2020</b> , 182, 685-712.e19	56.2	439
15	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. <i>Nature</i> , <b>2020</b> , 583, 459-468	50.4	2142
14	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. <i>Science</i> , <b>2020</b> , 370,	33.3	261
13	SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 28344-28354	11.5	201
12	Synergistic lethal mutagenesis of hepatitis C virus. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> ,	5.9	7
11	Contribution of a Multifunctional Polymerase Region of Foot-and-Mouth Disease Virus to Lethal Mutagenesis. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	3
10	Nucleolar Relocalization of RBM14 by Influenza A Virus NS1 Protein. <i>MSphere</i> , <b>2018</b> , 3,	5	5
9	Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	32
8	Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus. <i>Virus Research</i> , <b>2017</b> , 233, 105-112	6.4	21
7	Distance effects during polyprotein processing in the complementation between defective FMDV RNAs. <i>Journal of General Virology</i> , <b>2016</b> , 97, 1575-1583	4.9	1
6	Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3786-93	5.9	29

5	Multifunctionality of a picornavirus polymerase domain: nuclear localization signal and nucleotide recognition. <i>Journal of Virology</i> , <b>2015</b> , 89, 6848-59	6.6	17
4	Clonality and intracellular polyploidy in virus evolution and pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 8887-92	11.5	14
3	Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. <i>Journal of Virology</i> , <b>2014</b> , 88, 12098-111	6.6	57
2	Exploration of sequence space as the basis of viral RNA genome segmentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 6678-83	11.5	25
1	Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV-2 Replication in Cell Culture		2